NCT03255993View on ClinicalTrials.gov

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 23, 2017

Primary Completion Date

September 20, 2018

Study Completion Date

September 20, 2018

Conditions
Hypertension
Interventions
DRUG

SPH3127 50mg

SPH3127 50mg

DRUG

SPH3127 100mg

SPH3127 100mg

DRUG

Placebo matching to SPH3127 50mg

Placebo matching to SPH3127 50mg

DRUG

Placebo matching to SPH3127 100mg

Placebo matching to SPH3127 100mg

Trial Locations (1)

100029

The capital medical university affiliated Beijing anzhen hospital, Beijing

All Listed Sponsors
lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY

NCT03255993 - The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People | Biotech Hunter | Biotech Hunter